Literature DB >> 23323193

Acute mountain sickness without headache at low altitude.

Josef Finsterer1.   

Abstract

Entities:  

Year:  2012        PMID: 23323193      PMCID: PMC3545332          DOI: 10.1258/shorts.2012.12061

Source DB:  PubMed          Journal:  JRSM Short Rep        ISSN: 2042-5333


× No keyword cloud information.
Acute mountain sickness (AMS) may occur at altitudes below 3000 m and may be triggered by chronic stress and over-exercise.

Case report

A 45-year-old tourist developed AMS three hours after starting to ski in a glacier skiing-region in Austria. His history was noteworthy for chronic stress, coffee-overuse, chronic sleep-deprivation, and previous AMS, 14 years ago at ∼3000 m and six years ago at ∼5100 m. He occasionally trekked to altitudes of 1500–2500 m without problems. The night before suffering AMS he had slept for four hours at an altitude of 760 m, and had drunk 1 L of coffee in the morning but less during previous days. He did not take any azetazolamide prophylaxis before travelling to the glacier. After a 30-minute drive to the skiing-arena, he took the first cable car and went skiing for three hours without any problems (Table 1). After a strenuous ride off the regular slope he became tired and movements slowed down but recovered during ascent to 2678 m (Table 1). He skied down to 2450 m and although he needed a rest, he ascended to 2656 m. During this ascent at ∼11 h he recognized intense tiredness and progressive impairment of breathing. He developed nausea and had the urgent need to descend to lower altitudes. He skied down to 2450 m with an increasing number of stop-overs. On arrival he was dyspnoeic with a breathing rate of ∼50/min, panted for air, longed for oxygen, was tachycardious, recognized paresthesias of both hands and feet, and no longer able to recover despite resting. He managed to get on a cable car on his own, with slow motions, and descend to 1979 m. Despite this descent within four minutes and lying flat in the cabin, tachypnoea and tachycardia persisted, he became dizzy and feared he would immediately faint. When arriving at 1979 m he had difficulty leaving the cabin, to stay upright and to move. He was hardly able to lean on his sticks and took every effort not to faint. An employee of the lift-company helped the patient into a cable car and accompanied him on his further descent, during which tachypnoea and tachycardia did not resolve. He asked the employee to call the emergency services to give him oxygen and to transfer him to a hospital on arrival.
Table 1

Lift rides before and after AMS in the presented patient

TimeAVSATSDRSAMSADS
08:0591119798No0
08:15197824504No15 (slope)
08:40197824504No0
08:45245026568.5No10 (slope)
09:00245026568.5No0
09:10262929365.5No15 (slope)
09:35253028424No30 (off slope)
10:10241426116No15 (slope)
10:3522652678NPNo10 (slope)
10:55245026568.5Onset20 (slope)
11:30245019784YesDescent with lift
11:4519799118YesDescent with lift
12:30NANANAResolutionNA

AMS, acute mountain sickness; AVS, altitude at valley-station; ATS, altitude at top-station; DR, duration of ride (in minutes); SAMS, symptoms of AMS; ADS, approximate duration of skiing (in minutes); NP, not provided; NA, not applicable

Lift rides before and after AMS in the presented patient AMS, acute mountain sickness; AVS, altitude at valley-station; ATS, altitude at top-station; DR, duration of ride (in minutes); SAMS, symptoms of AMS; ADS, approximate duration of skiing (in minutes); NP, not provided; NA, not applicable After delayed arrival of the doctor at the valley station, he measured a blood pressure of 120/60 mmHg, rhythmic tachycardia (116 beats/min) and a breathing rate of 42/min. He interpreted the condition as psychogenic hyperventilation, and vigorously prompted the patient to voluntarily stop tachypnoea and tried to infuse 500 mL of sodium-chloride plus diazepam (10 mg), which the patient vehemently refused. During transport to the hospital, tachypnoea and tachycardia resolved, and on admission auscultation and blood pressure were normal, electrocardiography showed sinus-rhythm (87/min), normal breathing rate, and normal creatine kinase and D-dimer. Blood gas analysis and X-ray of the lung were normal. He was not given oxygen at any time when symptoms evolved. He dismissed himself against medical advice and despite some concern about the incident, went skiing the same day. He ascended to maximally 2000 m during the next two hours, but tolerated the strain with some indisposition and weird feeling. After sufficient sleep, he skied during the whole next day to a maximal altitude of 2074 m, without complaints. Two days after AMS, he went to the same glacier skiing-region, where he had experienced AMS, even to an altitude above 3000 m, and stayed there for the whole day, without any cardiac or respiratory problems.

Discussion

Altitude illness (AI) results from hypobaric hypoxia and comprises AMS and chronic mountain sickness, which may deteriorate to high-altitude pulmonary oedema (HAPE) or high-altitude cerebral edema (HACE).[1,2] AMS is the most frequent type of AI and characterized by headache, loss of appetite, nausea, anorexia, fatigue, sleep disturbance or lassitude within 6–12 h of gaining altitude.[3] In non-acclimatized patients and patients at risk for AI, AI may occur already below 3000 m. Severe AMS (Lake Louis score 7) was diagnosed in the presented patient despite the absence of headache, since no other causes of his complaints were detected (Table 2).[1,2] Tachypnoea was regarded as a manifestation of AMS, because it has been previously reported during AMS[4] and is regarded as part of the cardiovascular response to high altitude (increase in cardiac output, pulmonary artery pressure and blood pressure, tachypnoea and tachycardia).[5] Tachypnoea may even be periodic.[6] The diagnosis was supported by the fact that the condition started three hours after ascent and that the abnormalities immediately disappeared upon descent to <1000 m. An argument against AMS could be the early onset after ascent (3 h contrary to 6–12 h per definition).[3] Differential diagnoses excluded were pulmonary embolism, myocardial infarction, viral infection, cardiac arrhythmia or inhalation of toxic gases. Mild pulmonary embolism cannot be completely excluded, since no computed tomography scans of the lung were performed.
Table 2

Assessment of severity of AMS in the described patient according to the Lake Louise Score

Rating
Headache
 None0
 Mild1
 Moderate2
 Severe, incapacitating3
Gastrointestinal symptoms
 None0
 Poor appetite or nausea1
 Moderate nausea or vomiting2
 Severe nausea or vomiting3
Fatigue or weakness
 Not tired or weak0
 Mild fatigue/weakness1
 Moderate fatigue/weakness2
 Severe fatigue/weakness3
Dizziness/lightheadedness
 Not dizzy0
 Mild dizziness1
 Moderate dizziness2
 Severe dizziness, incapacitating3
Difficulty sleeping
 Slept as well as usual0
 Did not sleep as well as usual1
 Woke many times, poor sleep2
 Could not sleep at all3
Total score7

AMS, acute mountain sickness

A total score of 3–5 is interpreted as mild AMS, a score of >5 as severe AMS

Assessment of severity of AMS in the described patient according to the Lake Louise Score AMS, acute mountain sickness A total score of 3–5 is interpreted as mild AMS, a score of >5 as severe AMS The presented case is interesting for several points. Firstly, AMS developed at relatively low altitude. In most cases, AMS developed at altitudes >3000 m.[1-3] Only rarely does AMS develop at altitudes <3000 m.[4] Low-altitude AMS in the presented patient may be due to refraining from acclimatization, chronic stress, chronic sleep deprivation or the history of previous AMS. Usually, pulmonary function decreases with increasing altitude.[7] Risk factors, which generally predispose for AMS include rapid ascent, strenuous physical activity, young age, living at low altitude and a history of AI[8], of which four were the case in the presented patient. Secondly, triggers of AMS include hypobaric hypoxia, dehydration, increased physical exertion (over-exertion), infection or exsiccosis.[9] Triggers in the presented patient may be dehydration, excessive exercise, chronic stress, excessive consumption of coffee, sleep deprivation, non-acclimatization and the history of previous AMSs. However, he had climbed to such altitudes under similar conditions repeatedly before without complaints. Thirdly, the patient had already experienced two previous episodes of AMS. A general disposition for AI is rather unlikely, since he had repeatedly climbed to high altitudes without problems between the three episodes. Whether patients with a positive history for AMS carry an increased risk to experience relapsing AMS is unknown, but some authors regard previous AMS as a risk factor for a relapse.[8] Fourthly, the patient had not developed headache or a visual problem at any time during AMS, which is usually part of the clinical spectrum of AMS. Whether headache is truly a prerequisite for diagnosing AMS is under debate, since it was absent even in patients with HAPE.[10] Absence of headache could be explained by the absence of increased cerebral pressure, which is believed to cause headache in AI. The absence of headache was most likely due to the relatively low altitude at which microgravity is not large enough to result in an inflow/outflow mismatch of cerebral perfusion or hypoxia-induced pulmonary vasoconstriction and consecutive compromise of cerebral venous outflow.[11] In conclusion, AMS may occur at altitudes <3000 m and be triggered by chronic stress or over-exercise. Appropriate acclimatization even for altitudes <3000 m is recommended to prevent stress-triggered AMS. Oxygen should be available in emergency rooms of lift stations in high-altitude skiing areas. Absence of headache may strengthen the need to broaden the lower end of the clinical spectrum of AMS and to also include cases of pre-AMS, which generally are self-resolving and require only minimal intervention. Outcome of AMS is favourable upon immediate descent to low altitude.

DECLARATIONS

Competing interests

None declared

Funding

None

Ethical approval

Written informed consent to publish the article was obtained by the patient or next of kin.

Guarantor

JF

Contributorship

JF is the sole contributor

Acknowledgments

None

Reviewer

Rathai Anandanadesan
  11 in total

1.  High-altitude illness induced by tooth root infection.

Authors:  J Finsterer
Journal:  Postgrad Med J       Date:  1999-04       Impact factor: 2.401

Review 2.  High-altitude illness.

Authors:  Scott A Gallagher; Peter H Hackett
Journal:  Emerg Med Clin North Am       Date:  2004-05       Impact factor: 2.264

3.  Physiological adaptation of the cardiovascular system to high altitude.

Authors:  Robert Naeije
Journal:  Prog Cardiovasc Dis       Date:  2010 May-Jun       Impact factor: 8.194

4.  Variables contributing to acute mountain sickness on the summit of Mt Whitney.

Authors:  Dale R Wagner; Jamison D Fargo; Daryl Parker; Kevin Tatsugawa; Troy A Young
Journal:  Wilderness Environ Med       Date:  2006       Impact factor: 1.518

5.  Transient myoclonic jerks and restless legs during periodic tachypnea in acute mountain sickness.

Authors:  Josef Finsterer
Journal:  J Travel Med       Date:  2007 Nov-Dec       Impact factor: 8.490

6.  Altitude illness: risk factors, prevention, presentation, and treatment.

Authors:  David C Fiore; Scott Hall; Pantea Shoja
Journal:  Am Fam Physician       Date:  2010-11-01       Impact factor: 3.292

7.  Can migraine prophylaxis prevent acute mountain sickness at high altitude?

Authors:  M W Kim; M Kim
Journal:  Med Hypotheses       Date:  2011-11       Impact factor: 1.538

8.  Pulmonary ventilatory function decreases in proportion to increasing altitude.

Authors:  F Hashimoto; B McWilliams; C Qualls
Journal:  Wilderness Environ Med       Date:  1997-11       Impact factor: 1.518

9.  The headache of high altitude and microgravity--similarities with clinical syndromes of cerebral venous hypertension.

Authors:  Mark H Wilson; Christopher H E Imray; Alan R Hargens
Journal:  High Alt Med Biol       Date:  2011-11-16       Impact factor: 1.981

Review 10.  Work at high altitude and oxidative stress: antioxidant nutrients.

Authors:  E W Askew
Journal:  Toxicology       Date:  2002-11-15       Impact factor: 4.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.